Document is current
Any future updates will be listed below
-
Authors
Bourguignon, Lucie https://orcid.org/0000-0001-8049-6461
Lukas, Louis P. https://orcid.org/0000-0001-9307-0945
Guest, James D. https://orcid.org/0000-0003-0931-0286
Geisler, Fred H. https://orcid.org/0000-0002-0899-9045
Noonan, Vanessa https://orcid.org/0000-0003-3226-9218
Curt, Armin https://orcid.org/0000-0003-0136-8467
Brüningk, Sarah C. https://orcid.org/0000-0003-3176-1032
Jutzeler, Catherine R. https://orcid.org/0000-0001-7167-8271
-
Funding
Funding for this research was provided by:
Swiss Federal Institute of Technology Zurich
- License Information
-
More Information
Article History
Received: 4 July 2023
Accepted: 8 December 2023
First Online: 6 January 2024
Declarations
:
: Approval for this study (secondary analysis) was received by an institutional ethical standards committee on human experimentation at the University of British Columbia. The original Sygen clinical trial [–] also received ethical approval, but was conducted before clinical trials were required to be registered (i.e., no clinicaltrial.gov identifier available). All experiments were performed in accordance with relevant guidelines and regulations. Informed consent to participate was obtained from all of the participants as part of the original study.
: Not applicable.
: The authors declare no competing interests.
